INFANRIX

This brand name is authorized in Lithuania, New Zealand, Poland, United States

Active ingredients

The drug INFANRIX contains a combination of these active pharmaceutical ingredients (APIs):

1 Tetanus toxoid UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Tetanus toxoid

2 Diphtheria toxoid UNII IRH51QN26H - CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Diphtheria toxoid

3 Pertussis, purified antigen UNII QSN5XO8ZSU - BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED)

Read about Pertussis, purified antigen

4 Pertussis filamentous hemagglutinin UNII 8C367IY4EY - BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Pertussis filamentous hemagglutinin

5 Pertussis, purified antigen UNII I05O535NV6 - BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Pertussis, purified antigen

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07AJ52	Pertussis, purified antigen, combinations with toxoids	J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AJ Pertussis vaccines
Discover more medicines within J07AJ52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1007549
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 7344
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100224363
Country: US	FDA, National Drug Code	Identifier(s): 50090-2883, 58160-810